Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2024-04-28 05:44:58 ET Summary Vabysmo and Phesgo are still strong growth drivers for the company going forward, growing year over year in Q1 of 2024 by 108% and 70%, respectively. Mid-single digit sales growth is expected to remain with the pipeline that it has established thus f...
2024-04-26 12:01:50 ET Summary AbbVie's Q1 earnings beat estimates, with a smaller decline in Humira sales than expected. The company's next-generation drugs, Rinvoq and Skyrizi, are offsetting the decline in Humira sales. AbbVie's profitability will be weaker than in previous...
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
2024-04-24 16:16:00 ET Roche Holding AG (RHHBY) Q1 2024 Sales/ Trading Statement Conference Call April 24, 2024 08:00 AM ET Company Participants Thomas Schinecker - Chief Executive Officer, Roche Group Alan Hippe - Chief Financial & Information Officer Teresa...
2024-04-24 14:01:40 ET More on HOOKIPA Pharma Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts Hookipa to cut 30% of workforce in wake of Roche deal termination Seeking Alpha’s Quant Rating on HOOKIPA Pharma Historical ...
2024-04-24 10:00:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio meaningfully beat the benchmark MSCI EAFE Index, as well as the seconda...
2024-04-23 10:29:06 ET More on Edgewise Therapeutics Edgewise Therapeutics: Behind The Massive Rally Krystal Biotech, Candel, Edgewise gain after FDA fast track tags Seeking Alpha’s Quant Rating on Edgewise Therapeutics Historical earnings data for Edg...
2024-04-22 14:20:23 ET Summary Hookipa Pharma is conducting a call on 04/25/24 to share lead asset HB-200's pivotal trial design. A Phase 2a clinical update is due in 2Q'24. The company's shares closed at $0.733, with a valuation of approximately $72.53. Positive data ...
2024-04-19 14:48:33 ET More on Health Care Select Sector SPDR: XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among ...
2024-04-18 17:14:39 ET More on Roche Holding Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Roche: Strong Long-Term Potential Overshadowed Roche: The Recent Sell-Off Created A 30% Upside Potential Adaptimmune falls as Roche strategic...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
The obesity market has garnered much interest lately, ever since Novo Nordisk (NYSE: NVO) received FDA approval for its obesity drug Wegovy in 2021...
Thursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b trial of CT-388, a dual GLP-1/GIP r...
– Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) – – At week 24, 100% of CT-388 treated participants achieved >5% weight loss, 70...